Summary
Dexcom, Inc. (DXCM), a leader in continuous glucose monitoring (CGM) systems, filed its 10-K on February 14, 2022, detailing its business and financial performance for the fiscal year ending December 31, 2021. The company reported robust revenue growth of 27%, reaching $2.45 billion, driven by increased sales volume of its disposable sensors. Gross profit also saw a significant increase of 31% to $1.68 billion, reflecting improved manufacturing efficiencies and economies of scale. Key strategic initiatives include the development and approval of its next-generation G7 CGM system, which promises enhanced features like reduced size and a fully disposable design. Dexcom continues to expand its partnerships with insulin delivery system manufacturers and broaden its market reach, including targeting Type 2 diabetes patients not on intensive insulin therapy. The company maintains a strong liquidity position with $2.73 billion in cash, cash equivalents, and marketable securities, positioning it well for continued investment in product innovation and market expansion.
Financial Highlights
53 data points| Revenue | $2.45B |
| Cost of Revenue | $768.00M |
| Gross Profit | $1.68B |
| R&D Expenses | $517.10M |
| SG&A Expenses | $810.50M |
| Operating Expenses | $1.41B |
| Operating Income | $265.80M |
| Interest Expense | $18.80M |
| Net Income | $216.90M |
| EPS (Basic) | $0.56 |
| EPS (Diluted) | $0.53 |
| Shares Outstanding (Basic) | 386.90M |
| Shares Outstanding (Diluted) | 428.80M |
Key Highlights
- 1Dexcom reported a 27% year-over-year revenue increase, reaching $2.45 billion in 2021, driven by strong sales volume growth of its disposable CGM sensors.
- 2Gross profit grew by 31% to $1.68 billion, indicating improved manufacturing efficiencies and economies of scale.
- 3The company is actively developing its next-generation G7 CGM system, which aims to offer significant improvements in size and disposability, alongside faster warmup times.
- 4Dexcom's strategy includes expanding its market reach to include Type 2 diabetes patients not on intensive insulin therapy and strengthening partnerships with insulin pump manufacturers.
- 5The company ended 2021 with a strong liquidity position, holding $2.73 billion in cash, cash equivalents, and marketable securities.
- 6Dexcom continues to invest heavily in research and development, with R&D expenses increasing by 44% year-over-year, to support new product development and enhancements.
- 7The company is navigating a competitive landscape, including significant competition from established players like Abbott and Medtronic, and is focusing on product innovation, quality, and customer support as key differentiators.